文献速递脑血管病

真实世界中血管内治疗对缺血性卒中仍有效吗?十年随机对照试验与观察性研究的荟萃分析

Is Endovascular Treatment Still Good for Ischemic Stroke in Real World?: A Meta-Analysis of Randomized Control Trial and Observational Study in the Last Decade.
PubMed 文献 · Stroke · 2020-09-14

结果显示,在随机对照试验和正常卒中组中,EVT与更高的改良Rankin量表0-2分率和更低的死亡率相关;在严重卒中组(ASPECTS<6或缺血核心≥50 mL)中,EVT同样优于MT;但在轻度卒中组(NIHSS<6)中,EVT与MT的改良Rankin量表0-2分率无差异,且EVT与更高的死亡率和症状性颅内出血率相关。

要点

  • EVT是符合最新指南的 eligible 患者的一线选择。
  • 对于ASPECTS<6的患者,EVT优于MT,与指南一致。
  • 与指南相反,数据不支持对NIHSS<6的患者进行EVT。

核心结论

  • 随机对照试验和观察性研究证据支持EVT作为符合最新指南的 eligible 患者的一线选择。
  • 对于ASPECTS<6的患者,EVT优于MT,与指南一致。
  • 与指南相反,数据不支持对NIHSS<6的患者进行EVT。

研究设计与样本

  • 观察性研究按入院影像数据预分为轻度卒中组(NIHSS<6)、严重卒中组(ASPECTS<6或缺血核心≥50 mL)和正常卒中组。

主要发现

  • 在随机对照试验和正常卒中组中,EVT与更高的改良Rankin量表0-2分率和更低的死亡率相关。
  • 在正常卒中组中,EVT与更高的症状性颅内出血率相关;在随机对照试验中,EVT与MT的症状性颅内出血率无差异。
  • 在严重卒中组中,EVT与更高的改良Rankin量表0-2分率和更低的死亡率相关,症状性颅内出血率无差异。
  • 在轻度卒中组中,EVT与MT的改良Rankin量表0-2分率无差异,但EVT与更高的死亡率和症状性颅内出血率相关。

关键数值与推荐

  • 轻度卒中定义为NIHSS评分<6。
  • 严重卒中定义为ASPECTS<6或缺血核心≥50 mL。
  • 结局指标包括90天改良Rankin量表0-2分、死亡率和24小时症状性颅内出血。

临床怎么用

  • 对于符合最新指南的 eligible 患者,EVT应作为一线治疗选择。
  • 对于ASPECTS<6的患者,EVT仍可考虑,与指南推荐一致。
  • 对于NIHSS<6的轻度卒中患者,需谨慎评估EVT,因数据提示可能增加死亡率和症状性颅内出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Although endovascular treatment (EVT) for acute ischemic stroke is classified as I evidence, outcomes after EVT in real-world practice appear to be less superior than those in randomized clinical trials (RCTs). Additionally, the effect of EVT is unclear compared with medical treatment (MT) for patients with mild symptoms defined by National Institutes of Health Stroke Scale score <6 or with severe symptoms defined by Alberta Stroke Program Early CT Score <6. METHODS: Literatures were searched in big databases and major meetings from December 6, 2009, to December 6, 2019, including RCTs and observational studies comparing EVT against MT for patients with acute ischemic stroke. Observational studies were precategorized into 3 groups based on imaging data on admission: mild stroke group with National Institutes of Health Stroke Scale score <6, severe stroke group with Alberta Stroke Program Early CT Score <6 or ischemic core ≥50 mL, and normal stroke group for all others. Outcome was measured as modified Rankin Scale score of 0 to 2, mortality at 90 days, and symptomatic intracranial hemorrhage (sICH) at 24 hours. RESULTS: Fifteen RCTs (n=3694) and 37 observational studies (n=9090) were included. EVT was associated with higher modified Rankin Scale 0 to 2 rate and lower mortality in RCTs and normal stroke group, whereas EVT was associated with higher sICH rate in normal stroke group, and no difference of sICH rate appeared between EVT and MT in RCTs. In severe stroke group, EVT was associated with higher modified Rankin Scale 0 to 2 rate and lower mortality, whereas no difference of sICH rate was found. In mild stroke group, there was no difference in modified Rankin Scale 0 to 2 rate between EVT and MT, whereas EVT was associated with higher mortality and sICH rate. CONCLUSIONS: Evidence from RCTs and observational studies supports the use of EVT as the first-line choice for eligible patients corresponding to the latest guideline. For patients with Alberta Stroke Program Early CT Score <6, EVT showed superiority over MT, also in line with the guidelines. On the contrary to the guideline, our data do not support EVT for patients with National Institutes of Health Stroke Scale score <6.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhao Z, Zhang J, Jiang X, et al. Is Endovascular Treatment Still Good for Ischemic Stroke in Real World?: A Meta-Analysis of Randomized Control Trial and Observational Study in the Last Decade. Stroke. 2020. PMID: 32921259. doi:10.1161/STROKEAHA.120.029742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。